Johnson & Johnson today announced that it has provided a $5MM endowment to Research!America to create an annual award to recognize individuals and organizations working to make a profound difference in public health. This new category of awards will be presented annually as part of the Research!America Advocacy Awards Program, now in its 26th year. Johnson & Johnson is a founding member of the Research!America ...

- Johnson & Johnson (NYSE: JNJ) today announced that it has provided a $5MM endowment to Research!America to create an annual award to recognize individuals and organizations working to make a profound difference in public health. This new category of awards will be presented annually as part of the Research!America Advocacy Awards Program, now in its 26th year. Johnson & Johnson is a founding member of the Research!America alliance, which launched in 1989.  This year's winners include leaders who are addressing some of the biggest health challenges of our time, from smoking cessation to diversity in clinical trials to fueling collaboration to advance solutions for COVID-19.

"As part of the global public health community, Johnson & Johnson is delighted to collaborate with Research!America to honor the public health heroes whose energy and commitment have made a profound difference in advancing the health of entire populations," said William Hait , M.D., Ph.D., Global Head, Johnson & Johnson External Innovation. "Their work impacts all of us, and we are proud to celebrate their valuable contributions through endowing this Award."

While medicine is often focused on disease treatment, public health focuses on prevention of disease and injuries, and promoting safety and wellness through research, education and policy making.

"We are deeply appreciative of Johnson & Johnson's generous endowment focused on raising the profile of public health and its numerous heroes as they fight day in and day out to advance the public good," said Mary Woolley , president and CEO of Research!America. "For more than 30 years, Johnson & Johnson has been a highly valued strategic partner, contributing expertise, vision, and unwavering resolve to our goal of improving and saving lives through medical and public health research."

Johnson & Johnson has invited the honorees to share their stories as part of EUREKA MOMENTS, a series that chronicles the journeys of the people behind the breakthroughs that are improving the lives of millions around the world.  The series will air on the company's YouTube channel on Tuesdays at noon EST .

"The individuals and organizations honored with the inaugural Research!America Outstanding Achievement in Public Health Awards exemplify the vision, passion, and commitment that it takes to make a profound impact on the health and well-being of communities around the world," said Seema Kumar , Global Head, Office of Innovation, Global Health and Scientific Engagement, Johnson & Johnson. "We look forward to sharing the remarkable stories of how these public health champions have persevered against all odds and against seemingly impossible problems through the EUREKA MOMENTS series."

Learn more about this year's honorees:

  • Three honorees will receive the Outstanding Achievement in Public Health Award , which recognizes individuals for their extraordinary work and enormous contributions to public health.
    • Matthew Myers , president, Campaign for Tobacco-Free Kids, and Bill Novelli , founder and chair, Campaign for Tobacco-Free Kids, professor and founder, Business for Impact, McDonough School of Business, Georgetown University . Myers and Novelli are longtime leaders in the fight to reduce tobacco use and its deadly consequences. Their advocacy efforts have led to drastic decreases in both youth and adult smoking on a global scale since the Campaign for Tobacco-Free Kids was founded in 1996.
    • Vivian W. Pinn , MD , inaugural director, NIH Office of Research on Women's Health (retired). Dr. Pinn's many contributions to public health include her leadership in assuring greater inclusion of women and minorities in clinical trials and promoting the consideration of sex differences in the formulation and execution of research studies.
  • Christopher Murray , MD, DPhil , professor and chair of health metrics sciences and director, Institute for Health Metrics and Evaluation, University of Washington School of Medicine is the recipient of the Building the Foundation Award , which recognizes one or more individuals whose basic research discoveries have played a pivotal role in advancing public health. Dr. Murray created the first COVID-19 global forecast that decision makers have used as a roadmap for ending the pandemic, and  state-level forecasts that have been essential to on-the-ground response efforts.
  • Ashish K. Jha , MD, MPH , dean, Brown University School of Public Health, is the recipient of the Meeting the Moment for Public Health Award , which recognizes an individual or organization that has been a "clear voice," playing a key role in communicating public health information and developments to members of the public. Dr. Jha's masterful ability and tireless commitment to conveying key information about COVID-19 to a wide array of audiences has helped keep the public informed and combat mis- and disinformation.
  • Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) is the recipient of the Rapid Translation Award , which recognizes a public-private partnership that has made a critical contribution to public health progress. ACTIV made crucial contributions to the rapid-pace development of COVID-19 treatments and vaccines by designing master protocols, establishing national standards, and identifying best practices and collaboration opportunities to improve every stage of the prevention and treatment R&D pipeline.

About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/johnson--johnson-endows-researchamerica-outstanding-achievement-in-public-health-awards-301420352.html

SOURCE Johnson & Johnson

News Provided by PR Newswire via QuoteMedia

IDBS Polar Insight Brings Advanced Data Analytics and Visualization to BioPharma Lifecycle Management

IDBS, a Danaher (NYSE:DHR) operating company, announced Polar Insight, bringing new advanced data analytics and visualization tools to the Polar BioPharma Lifecycle Management (BPLM) platform.

Extracting valuable insights from process and quality data across the biopharmaceutical lifecycle is a time consuming and error prone process, requiring laborious manual work and multiple steps.

Keep reading... Show less

Medtronic receives Health Canada licence for GI Genius intelligent endoscopy module with artificial intelligence system for colonoscopy

Transformative AI System Enhances Colorectal Cancer Detection Capabilities

 Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT) — the global leader in medical technology — announced it has received a Health Canada licence for the GI Genius™ intelligent endoscopy module. GI Genius is a computer-aided detection (CADe) system that uses artificial intelligence (AI) to highlight regions of the colon suspected to have visual characteristics consistent with different types of mucosal abnormalities.

Keep reading... Show less
Beyond Medical Technologies Ramps Up COVID Mask Manufacturing in Response to New South Africa COVID Variant

Beyond Medical Technologies Ramps Up COVID Mask Manufacturing in Response to New South Africa COVID Variant

Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM4) ("Beyond Medical" or the "Company") is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. ("Micron Technologies").

Keep reading... Show less
Leveljump Q3 Earnings and Results; Record Quarterly Revenues

Leveljump Q3 Earnings and Results; Record Quarterly Revenues

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce today it has reported financial results for the third fiscal quarter ended September 30th, 2021. All amounts are expressed in Canadian dollars.

Financial and Operational Highlights

Keep reading... Show less

Thermo Fisher Scientific Confirms Detection of SARS-CoV-2 in Samples Containing the Omicron Variant with its TaqPath COVID-19 Tests

- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today confirmed that its polymerase chain reaction (PCR) TaqPath COVID-19 Combo Kit *, and TaqPath COVID-19 CE-IVD RT-PCR Kit *, which test for the presence of SARS-CoV-2, are not impacted by the emerging B.1.1.529, or Omicron variant, enabling accurate test results.

The Omicron variant, which was designated a " variant of concern " by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone. The WHO has reported that preliminary evidence suggests an increased risk of transmission compared to other variants of concern. This designation and information are leading to renewed travel restrictions and research to examine the variant's impact on efficacy of existing vaccines and tests. The WHO and European Centers for Disease Control have both reported that using S-gene target failure (SGTF) of the PCR assays as a proxy for the variant helped to identify Omicron. Cases of the variant were first identified in South Africa and have now been reported in at least a dozen countries around the world.

Keep reading... Show less
UPDATED - Leveljump Healthcare Corp. Announces 14.6% Minority Investment in Real Time Medical

UPDATED - Leveljump Healthcare Corp. Announces 14.6% Minority Investment in Real Time Medical

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that, subject to regulatory approval, it has agreed to acquire an outstanding 14.6% minority equity interest in Real Time Medical Inc. ("RTM"), a private Ontario company, in exchange for 2,494,576 units (a "Unit") of Leveljump. Each Unit will be issued at a price of $0.66 per Unit with each Unit being comprised of three (3) Leveljump common shares at a deemed price of $0.22 per share and one (1) share purchase warrant of Leveljump, each warrant entitling the holder to acquire one additional common share of Leveljump at a price of $0.35 per common share on or before December 31, 2023.

The equity interest in RTM was acquired through a mini-tender offer to the shareholders of RTM dated November 1, 2021 whereby JUMP offered to acquire up to 19.9% of RTM in exchange for the Units. The holders of the RTM shares who have tendered are all accredited investors.

Keep reading... Show less

Top News

Related News